Teva acquires BioXcel neuroscience assets including BXCL501 for up to $125 million
Teva has acquired worldwide rights to BioXcel's BXCL501 neuroscience programme and approved IGALMI product in an asset transaction worth up to $125 million.
The completed acquisition transfers specified BioXcel Therapeutics assets to Teva, including investigational BXCL501 dexmedetomidine sublingual film and the FDA-approved hospital-use product IGALMI, following a US bankruptcy court-supervised sale.
Teva will pay $57.5 million upfront and may make up to $67.5 million in additional regulatory and sales-related payments, while BXCL501 remains under FDA review for potential at-home treatment of acute agitation associated with schizophrenia or bipolar disorder in adults.
Field | Content |
Article Type | Deals |
Acquirer | Teva Pharmaceutical Industries |
Asset Seller | BioXcel Therapeutics |
Deal Type | Acquisition of specified pharmaceutical assets and worldwide rights |
Transaction Status | Completed |
Announcement Date | 27 October 2026 |
Transaction Process | US bankruptcy court-supervised asset sale |
Acquired Development Asset | BXCL501 |
Acquired Approved Product | IGALMI |
Active Ingredient | Dexmedetomidine |
Drug Formulation | Sublingual film |
Therapeutic Area | Neuroscience; psychiatry |
Investigational Indication | At-home treatment of acute agitation associated with schizophrenia or bipolar I or II disorder in adults |
Existing Approved Use | IGALMI for hospital-use treatment of acute agitation in its approved patient population |
BXCL501 Regulatory Status | Under FDA review for proposed at-home use; not approved for that use in supplied summary |
Acquired Rights | Worldwide rights to specified assets |
Upfront Payment | $57.5 million |
Contingent Payments | Up to $67.5 million |
Maximum Transaction Value | Up to $125 million |
Contingent Payment Triggers | Regulatory and sales-related milestones |
Company Acquisition Status | Teva acquired specified assets, not BioXcel Therapeutics as a company |
What Happened | Teva completed an acquisition of BioXcel neuroscience assets following a bankruptcy court-supervised sale. |
Why It Matters | The transaction strengthens Teva's neuroscience portfolio with an approved agitation treatment and a related investigational at-home treatment opportunity. |
Strategic Rationale | Expand Teva's innovative neuroscience pipeline and potential treatment options for acute agitation. |
Key Takeaway | Teva secured worldwide rights to BXCL501 and IGALMI for $57.5 million upfront plus up to $67.5 million in contingent payments. |
What to Watch | FDA review of the proposed at-home indication, regulatory decisions, product integration, commercial development and milestone achievement. |
Primary Source | Teva Pharmaceutical Industries |
Primary Source URL | https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Acquires-Worldwide-Rights-to-BXCL501-Further-Expanding-Innovative-Neuroscience-Pipeline/default.aspx |
Relevant Date | 27 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Commenti